

Scientific Report

concerning the implementation of project 8/02.05.2018 in the period May-December 2018

Obtaining and purifying mutants of *K. pneumoniae* NhaB

Table of contents

| | |
|-----------------------------------------------------------------------------------------------------|----|
| Introduction..... | 2 |
| Materials and Methods..... | 4 |
| Materials | 4 |
| Methods | 4 |
| Results and discussion | 7 |
| Objective 1.1. Project management | 7 |
| Objective 1.2. Obtaining plasmids containing mutants of KpNhaB in the expression vector pET21d | 7 |
| Objective 1.3. Expression of KpNhaB N32A, D146A, D146E, N396A, D404A and D404E in E. coli .. | 7 |
| Objective 1.4. Result dissemination..... | 8 |
| Conclusions..... | 9 |
| References..... | 10 |

Introduction

All organisms require mechanisms for the regulation of the intracellular Na^+ concentration, as excessive amounts can lead to cell stress and death [1]. One system through which the intracellular Na^+ concentration is regulated is represented by membrane transporters called Na^+/H^+ exchangers or antiporters, which exchange n Na^+ ions with m H^+ ions [2]. If $n = m$, no net electrical charge is carried over the membrane and the exchanger is *electroneutral*. If $n < m$ (or, possibly, $m < n$), net charge is transported over the membrane and the exchanger is *electrogenic*.

In addition to Na^+ homeostasis, Na^+/H^+ exchangers also play a role in the regulation of intracellular pH and cell volume [3]. As the processes influenced by Na^+/H^+ exchangers are both interlinked and sensitive, a fine balance has to be achieved by the regulation of exchange activity. Excessive Na^+ export activity, though potentially beneficial through the reduction of the amount of intracellular Na^+ , can lead to over-acidification of the cell [1, 4]. At the other extreme, excess H^+ export in order to compensate for an acidic cytoplasm can lead to undesired accumulation of high amounts of Na^+ inside the cell. As a first consequence, Na^+/H^+ exchange activity is highly regulated through what we have shown to be a simple mechanism [1, 4] that relies on the competition between Na^+ and H^+ for a single binding site. As a second consequence, many organisms employ several Na^+/H^+ exchange systems, some electrogenic, some electroneutral, each tuned for a particular optimum range of operation.

One such organism is the pathogenic bacterium *Klebsiella pneumoniae*, whose genome encodes for 4 Na^+/H^+ exchangers belonging to the NhaA family (KpNhaA1, KpNhaA2, both electrogenic), the NhaB family (KpNhaB, electrogenic) and the NhaP family (KpNhaP2, electroneutral). In a previous study, we have analysed the activity of *K. pneumoniae* Na^+/H^+ exchangers and, in particular KpNhaB [5]. We have shown that, despite belonging to a different transport superfamily compared to the better investigated NhaA exchangers, KpNhaB follows a similar competition-based mechanism. Furthermore, we were able to do a full electrophysiological characterization of KpNhaB and determine kinetic parameters for the wild type protein. Our study [5] represented the first detailed characterization of an NhaB-class Na^+/H^+ exchanger. However, the NhaB family still remains sadly under-investigated. In particular, only few studies have tried to identify essential amino acid residues in NhaB proteins [6, 7]. All of them have assessed function through an assay involving the dequenching of a fluorescent dye, acridine orange or 9-amino-6-chloro-2-methoxyacridine (ACMA), which has its limitations, in particular regarding the dynamic range and the quantitative information that can be obtained [8].

The aim of the present project is to investigate the effect of several point mutations on the function of KpNhaB. All mutations will be performed on Asp or Asn residues thought to be present in transmembrane

helices of KpNhaB, according to the alignment of the sequence of KpNhaB to the putative transmembrane domains of NhaB from *V. alginolyticus* [6] (Figure 1). Asp or Asn residues present in membrane helices were chosen as these residues are commonly found in the binding sites of Na⁺/H⁺ exchangers [1, 4]. Furthermore, mutation of Asp147 in the NhaB exchanger from *V. alginolyticus* (VaNhaB) was shown to impair transport function [9].




Figure 1. Residues that will be mutated in KpNhaB are shown by black diamonds. TM denotes putative transmembrane helices. White diamonds denote residues that will be mutated in case there is no significant effect of performing any of the initial set of mutations. VaNhaB = NhaB exchanger from *V. alginolyticus*. EcNhaB = NhaB exchanger from *E. coli*.

The mutants that will be produced in this project are: N32A, D146A, D146E, D404A, D404E, N396A, for a total of four mutations of two Asp residues (to either the similarly charged Glu residue or to a non-polar Ala) and two mutations of two Asn residues to a non-polar alanine. Following production of these mutants, they will be reconstituted into proteoliposomes and characterized by solid supported membrane (SSM)-based electrophysiology, an investigative technique highly suitable for analysis of prokaryotic transporter function [10] that we also employed for characterization of the KpNhaB WT [5].

The present report details the first phase of the project, the aim of which was the production of the 6 KpNhaB mutants. As shown below, **all objectives of Phase 1 were successfully completed and functional proteoliposomes of all mutants were obtained.** The project can proceed to Phase 2 where the full electrophysiological characterization of mutants will be performed.

Materials and Methods

Materials

Genetic constructs

The KpNhaB WT gene (Strain 342, Uniprot accession number: B5XQ77) codon-optimized for expression in *E. coli* and inserted in the pET-21d(+) expression vector was used as a template for site-directed mutagenesis.

Bacterial strains

All cloning work was performed in the *E. coli* XL-1 Blue strain (Agilent Technologies, Santa Clara, CA, USA). Expression of proteins for production purposes was performed in the *E. coli* BL21(DE3) strain.

Chemicals

Unless otherwise stated, chemicals were produced by Carl Roth (Karlsruhe, Germany). 1,2-diphytanoyl-sn-glycero-3-phosphocholine and *E. coli* polar lipids were produced by Avanti Polar Lipids (Alabaster, AL, USA). Ultrapure water was produced using a Millipore MiliQ water purification system (Merck Millipore, Darmstadt, Germany). Bradford reagent was purchased from Bio-Rad Laboratories (Hercules, CA, USA).

Methods

Site-directed mutagenesis

Mutagenesis was performed using the Quikchange kit from Stratagene (Agilent Technologies, Santa Clara, CA, USA). In brief, the technique uses a supercoiled double stranded DNA plasmid as template. Two oligonucleotide primers were designed for each mutant (Table 1) containing the desired mutated bases in the middle part of the primer. The primers were extended by temperature cycling using PfuUltra DNA polymerase (Agilent Technologies, Santa Clara, CA, USA), resulting in a product containing staggered nicks. Following temperature cycling (Table 2), the product was treated with the enzyme *DpnI* (New England Biolabs, Ipswich, MA, USA) in order to digest the methylated DNA template. The resulting DNA was then used to transform XL1-Blue *E. coli* competent cells. These were grown overnight on ampicillin-agar plates, after which clones were selected in order to check for success of the mutation. DNA Mini preps were performed using the QIAprep Spin Miniprep kit (Qiagen, Hilden, Germany).

Sequences of mutated constructs were verified by sequencing performed by Eurofins Genomics (Ebersberg, Germany). Primers used for sequencing were standard Eurofins primers T7: TAA TAC GAC TCA CTA TAG GG and T7term: CTA GTT ATT GCT CAG CGG T.

Table 1. Mutagenic primers used for obtaining KpNhaB mutants. Capital letters denote bases unchanged from the template sequence.

| Mutant | Mutation | Primer sequence |
|--------|----------|----------------------------------------------|
| N32A | AAC-gcC | GATTATTTTTCTGATTGTGgcCCCGCTGGTGTTCGCGGTTGC |
| | | GCAACCGCGAACACCAGCGGGgcCACAATCAGAAAAATAATC |
| D146A | GAC-GcC | CCTGAGCGCGTTTTCTGGcCGCGCTGACCGTGGTTGC |
| | | GCAACCACGGTCAGCGCGgCCAGAAACGCGCTCAGG |
| D146E | GAC-GAa | CCTGAGCGCGTTTTCTGGAAgCGCGCTGACCGTGGTTGC |
| | | GCAACCACGGTCAGCGCGtTCCAGAAACGCGCTCAGG |
| N396A | AAC-gcC | GCCTGTTCTACCTGTTTgcCGGTCTGCTGAGCAGCATCAGC |
| | | GCTGATGCTGCTCAGCAGACCGgcAAACAGGTAGAACAGGC |
| D404A | GAT-GcT | GGTCTGCTGAGCAGCATCAGCGcTAACGTGTTTCGTTGGCACCG |
| | | CGGTGCCAACGAACACGTTAgCGCTGATGCTGCTCAGCAGACC |
| D404E | GAT-GAg | GGTCTGCTGAGCAGCATCAGCGAgAACGTGTTTCGTTGGCACCG |
| | | CGGTGCCAACGAACACGTTcTCGCTGATGCTGCTCAGCAGACC |

Table 2. Temperature cycling program for KpNhaB mutations.

| Step no. | Temperature (°C) | Time (s) | No. of cycles |
|----------|------------------|----------|---------------|
| 1. | 95 | 30 | - |
| 2. | 95 | 30 | 30 |
| 3. | 70 | 30 | |
| 4. | 72 | 480 | |
| 5. | 72 | 600 | - |

Protein overexpression and purification

Transformation of chemically competent cells was performed via heat shock (42 °C), using 50 ng of DNA.

Protein expression and purification were performed as previously described for KpNhaB WT [5]. In brief, bacteria were grown at 37 °C in LB medium, containing (per liter) 10 g tryptone, 5 g yeast extract and 10 g NaCl. The medium also contained 100 µg/mL carbenicillin. Cells were grown until they reached an optical density at 600 nm (OD_{600}) of 0.6 – 0.8 and then expression was induced by addition of IPTG (0.75 mM). Cells were collected after 2.5 hours via centrifugation.

Everted membrane vesicles were prepared via a French Press pressure cell [11] and resuspended in buffer containing Tris 10 mM (titrated to pH 7.5 with HCl), 250 mM sucrose and 140 mM choline chloride. Total protein concentration was determined according to the Bradford method [12].

Purification was performed by using Immobilized Metal Affinity Chromatography (IMAC) employing Ni-NTA Agarose (Qiagen, Hilden, Germany). Protein concentration was determined spectrophotometrically at 280 nm.

Western blot

SDS-PAGE and Western blot were performed essentially as described [13]. The marker used was PageRuler Protein Ladder 10 to 180 kDa (Thermo Fisher Scientific, Bonn, Germany). Antibodies used were PentaHis (Qiagen, Hilden, Germany) and polyclonal goat anti-mouse immunoglobulin (P0447 Dako, Agilent Technologies, Santa Clara, CA, USA). Chemiluminescence was used for detection employing SuperSignal West Pico Chemiluminescent Substrate (Thermo Fisher Scientific, Bonn, Germany).

Functional reconstitution into proteoliposomes

Reconstitution of proteins into proteoliposomes was performed as previously described for KpNhaB WT [5] at a lipid-to-protein ratio (LPR) of 10 (w:w).

Fluorescence measurements

Fluorescence measurements were performed using a Hitachi F4500 Fluorimeter (Hitachi High-Technologies Corporation, Tokyo, Japan) at $\lambda_{exc} = 495$ nm and $\lambda_{em} = 530$ nm. The measurement buffer contained 10 mM MES (titrated to the indicated pH using Tris), 140 mM choline chloride, 5 mM $MgCl_2$, 2 µM acridine orange. Vesicles containing 100 µg total protein were added and their acidification (and thus fluorescence quenching) was induced by addition of 5 mM Tris-D-lactate. After reaching steady-state fluorescence, dequenching was induced by addition of 50 mM Na^+ . Finally, the pH gradient was dissipated by addition of 20 mM NH_4Cl .

Results and discussion

The following section lists the objectives of the project in the order in which they are present in the execution plan of the project and describes the steps undertaken for the achievement of each objective.

Objective 1.1. Project management

The project management objective involved ensuring that all materials and required equipment were available for the well function of the project.

Thus, the oligonucleotide primers required for the site-directed mutagenesis reactions were designed. These were then ordered for synthesis with the help of Prof. Klaus Fendler from the Max Planck Institute of Biophysics in Frankfurt. For long term storage of biological sample a freezer capable of achieving temperatures in the range as low as -45°C was ordered. Additionally, experimental protocols that will be used for the protein expression were reviewed in order to ensure availability of all necessary chemicals.

Objective 1.2. Obtaining plasmids containing mutants of KpNhaB in the expression vector pET21d

The present objective was achieved. A detailed description has been reported to the contracting authority and can be released by request to the project director.

Objective 1.3. Expression of KpNhaB N32A, D146A, D146E, N396A, D404A and D404E in E. coli

1.3.1. Transforming E. coli BL21(DE3) with the plasmids. Obtaining inverted membrane vesicles.

The present objective was achieved. A detailed description has been reported to the contracting authority and can be released by request to the project director.

1.3.2. Verifying expression of the mutants using Western Blot

The present objective was achieved. A detailed description has been reported to the contracting authority and can be released by request to the project director.

1.3.3. Initial tests of mutant functionality using fluorimetry

The present objective was achieved. A detailed description has been reported to the contracting authority and can be released by request to the project director.

1.3.4. Purification of mutant proteins and reconstitution into proteoliposomes

The present objective was achieved. A detailed description has been reported to the contracting authority and can be released by request to the project director.

Objective 1.4. Result dissemination

1.4.1. Creating and updating the project's website

The project's website was established at the address: <http://octaviancalinescu.ro/pn-iii-p1-1-1-pd2016-0802/>. It contains the identification data for the project, the team's composition and the summary of the proposed research activity. In addition, the website lists the dissemination activities performed in Phase 1 (conference attendance and accepted journal article).

1.4.2. Conference attendance

The project's initial results and outlook were presented in this phase in the form of a poster at the 15th National Conference of Biophysics that took place in Bucharest between the 7th and the 10th of September 2018:

1. Patino-Ruiz, M., Ganea, C., Fendler, K., Călinescu, O., "The Na⁺/H⁺ Exchanger NhaB from *Klebsiella pneumoniae* – A Model System for Electrophysiological Studies.", 15th National Conference of Biophysics, 07-10 september 2018, Bucharest, Romania, ISSN 2248-0749.

The abstract of the presentation was published in the Book of Abstracts, ISSN 2248-0749. Additionally, the poster presentation received a "Best Poster" award from the organizers of the conference.

1.4.3. Articles published

The project's director work on mutations relevant to the Na⁺/H⁺ exchanger transport mechanism has led to the publication of an ISI article in The Journal of Biological Chemistry (2017 Impact Factor 4.25):

1. Patino-Ruiz, M., Dwivedi, M., Călinescu, O., Karabel, M., Padan, E., Fendler, K. 2018. “Replacement of Lys-300 with a glutamine in the NhaA Na⁺/H⁺ antiporter of Escherichia coli yields a functional electrogenic transporter”, J. Biol. Chem. doi: 10.1074/jbc.RA118.004903.

Conclusions

This first phase of the project was focussed on preparing all necessary materials for the activities of phase 2. In particular, all mutants of KpNhaB were obtained and overexpressed in *E. coli*. Everted membrane vesicles were prepared to test functionality of the mutants. These were then subjected to purification and the purified transporters were reconstituted into proteoliposomes.

All objectives of Phase 1 were successfully achieved. The project is ready to proceed to Phase 2.

References

1. Calinescu, O. and K. Fendler, *A universal mechanism for transport and regulation of CPA sodium proton exchangers*. Biol Chem, 2015. **396**(9-10): p. 1091-6.
2. Padan, E. and M. Landau, *Sodium-Proton (Na(+)/H(+)) Antiporters: Properties and Roles in Health and Disease*. Met. Ions Life Sci., 2016. **16**: p. 391-458.
3. Brett, C.L., M. Donowitz, and R. Rao, *Evolutionary origins of eukaryotic sodium/proton exchangers*. Am J Physiol Cell Physiol, 2005. **288**(2): p. C223-39.
4. Calinescu, O., et al., *Keeping it simple, transport mechanism and pH regulation in Na⁺/H⁺ exchangers*. J Biol Chem, 2014. **289**(19): p. 13168-76.
5. Patino-Ruiz, M., et al., *Competition is the basis of the transport mechanism of the NhaB Na⁺/H⁺ exchanger from Klebsiella pneumoniae*. PLoS One, 2017. **12**(7): p. e0182293.
6. Enomoto, H., et al., *Topological study of Vibrio alginolyticus NhaB Na⁺/H⁺ antiporter using gene fusions in Escherichia coli cells*. Biochim Biophys Acta, 1998. **1370**(1): p. 77-86.
7. Kiriya, W., et al., *Diversities and similarities in pH dependency among bacterial NhaB-like Na⁺/H⁺ antiporters*. Microbiology, 2013. **159**(Pt 10): p. 2191-9.
8. Calinescu, O., et al., *Species differences in bacterial NhaA Na⁺/H⁺ exchangers*. FEBS Lett, 2014. **588**(17): p. 3111-6.
9. Nakamura, T., et al., *Residue aspartate-147 from the third transmembrane region of Na(+)/H(+) antiporter NhaB of Vibrio alginolyticus plays a role in its activity*. J Bacteriol, 2001. **183**(19): p. 5762-7.
10. Bazzone, A., et al., *Introduction to solid supported membrane based electrophysiology*. J Vis Exp, 2013(75): p. e50230.
11. Rosen, B.P., *Ion extrusion systems in Escherichia coli*. Methods Enzymol, 1986. **125**: p. 328-36.
12. Bradford, M.M., *A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding*. Anal Biochem, 1976. **72**: p. 248-54.
13. Laemmli, U.K., *Cleavage of structural proteins during the assembly of the head of bacteriophage T4*. Nature, 1970. **227**(5259): p. 680-5.